It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

medicine

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Japan health ministry panel endorses nasal flu vaccine for children

National / Science & Health Feb 28, 2023

Japan health ministry panel endorses nasal flu vaccine for children

by Tomoko Otake

Based on the results of a clinical trial involving children in Japan, the panel agreed that FluMist Quadrivalent is safe and effective in preventing the flu.

Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval

Business / Corporate Feb 27, 2023

Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval

CEO Isao Teshirogi said he expects U.S. approval of the drug could come by the winter of 2024, pending a late-stage trial.

A refreshing gamble on Crispr delivery

Commentary / World Feb 27, 2023

A refreshing gamble on Crispr delivery

by Lisa Jarvis

Biotech startup Aera is trying to shake up the always-just-out-of-reach field of genetic medicine.

Japan moves toward approving abortion pill in major shift

National | EXPLAINER Feb 27, 2023

Japan moves toward approving abortion pill in major shift

by Kathleen Benoza

Currently, surgery is the only option available to terminate a pregnancy in Japan.

Shionogi says its drug Xocova may reduce risks of long COVID symptoms

National / Science & Health Feb 22, 2023

Shionogi says its drug Xocova may reduce risks of long COVID symptoms

by Tomoko Otake

For 14 major symptoms of COVID-19, 14.5% of those given Xocova reported at least one of the symptoms six months after the start of treatment, compared with 26.3% who were given a placebo.

One-size-fits-all COVID-19 booster plan needs a rethink

Commentary / World Jan 30, 2023

One-size-fits-all COVID-19 booster plan needs a rethink

by Faye Flam

Public health officials should recognize that additional COVID-19 booster shots should now be a more nuanced decision.

Priority review status given to Alzheimer's drug developed by Eisai and Biogen

National Jan 30, 2023

Priority review status given to Alzheimer's drug developed by Eisai and Biogen

The companies said priority review in Japan is granted to new medicines recognized as having high medical utility for serious diseases.

Updated COVID-19 vaccines prevented illness from latest variants, CDC says

World Jan 26, 2023

Updated COVID-19 vaccines prevented illness from latest variants, CDC says

The analysis found that the updated vaccine helped prevent illness in people who had previously received two to four doses of the original COVID-19 vaccine.

China COVID-19 deaths exceed 12,600 in week before Lunar New Year

Asia Pacific Jan 22, 2023

China COVID-19 deaths exceed 12,600 in week before Lunar New Year

There were 12,658 COVID-19-linked deaths at hospitals between Jan. 13 and 19, the Chinese Center for Disease Control and Prevention said in a statement.

Kishida to encourage debate on COVID-19 classification downgrade

National Jan 20, 2023

Kishida to encourage debate on COVID-19 classification downgrade

COVID-19 is currently categorized as equivalent to a Class 2 pathogen, such as tuberculosis and avian flu.

COVID immunity lasts at least a year after infection plus shots, study says

World / Science & Health Jan 19, 2023

COVID immunity lasts at least a year after infection plus shots, study says

The combination prevented more than 97% of severe disease or hospitalization for up to 12 months after infection or initial immunization.

In China, no easy way to get Pfizer's COVID drug Paxlovid

Asia Pacific Jan 16, 2023

In China, no easy way to get Pfizer's COVID drug Paxlovid

Beijing has acknowledged that supplies are still insufficient to meet demand, even as millions of courses of the treatment were shipped to the country recently.

« 1 … 6 7 8 … 46 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times